Global Leading Market Research Publisher QYResearch announces the release of its latest report “Inhaled Corticosteroids (ICS) Medications – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Inhaled Corticosteroids (ICS) Medications market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Asthma and COPD patients require daily anti-inflammatory therapy to prevent exacerbations – but oral corticosteroids cause systemic side effects. Inhaled corticosteroids (ICS) solve this with targeted airway delivery via dry powder or metered-dose inhalers, minimizing systemic absorption. Key drivers include asthma prevalence, GINA guideline recommendations, and generic ICS availability.
The global market for Inhaled Corticosteroids (ICS) Medications was estimated to be worth US$ 3,512 million in 2025 and is projected to reach US$ 4,474 million, growing at a CAGR of 3.6% from 2026 to 2032. In 2024, the average global price is around US$ 18.7 per unit, with total sales reaching approximately 182 million units.
Inhaled corticosteroids (ICS) are prescription medications that help reduce inflammation in the lungs. They are typically used daily to prevent asthma attacks and are sometimes prescribed for chronic obstructive pulmonary disease (COPD) or other respiratory conditions. ICS medications are commonly delivered via dry powder inhalers, allowing targeted treatment in the airways while minimizing systemic side effects. Examples include Beclomethasone dipropionate (Qvar®), Budesonide (Pulmicort®), Ciclesonide (Alvesco®), Fluticasone (Arnuity®, Flovent®), and Mometasone (Asmanex®).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098301/inhaled-corticosteroids–ics–medications
Market Segmentation & Key Players
The Inhaled Corticosteroids (ICS) Medications market is segmented as below:
Leading Suppliers: GSK, Chiesi Farmaceutici, Teva Pharmaceutical, Sumitomo Pharma, Cipla, Glenmark Pharmaceuticals, Orion Corporation, Bausch Health, Viatris, Novartis, Covis Pharma, Zentiva, AstraZeneca, Lunan Better Pharmaceutical, Jewim Pharmaceutical, Shanghai Pharmaceuticals, Zhejiang Xianjun Pharmaceutical, Anhui Wellman Pharmaceutical.
Segment by Type: Beclomethasone Dipropionate | Budesonide | Ciclesonide | Fluticasone | Mometasone | Others
Segment by Application: Asthma | COPD | Others
Exclusive Industry Insights
Discrete inhaler manufacturing: ICS medications are formulated as micronized API (<5μm) blended with carrier lactose (for DPIs) or suspended in HFA propellant (for MDIs). Device engineering is critical: consistent dose delivery despite variable patient inhalation flow rates.
Technical differentiation – ICS molecules:
| Molecule | Brand | Dosing Frequency | Prodrug | Relative Potency |
|---|---|---|---|---|
| Fluticasone propionate | Flovent | Twice daily | No | High |
| Budesonide | Pulmicort | Twice daily | No | Medium |
| Beclomethasone | Qvar | Twice daily | Yes (to active) | Medium |
| Ciclesonide | Alvesco | Once daily | Yes (lung-activated) | Medium |
| Mometasone | Asmanex | Once/twice daily | No | High |
Recent 6-month data (Oct 2025 – Mar 2026):
- Fluticasone largest segment (38% revenue), established market leader.
- Budesonide fastest-growing (CAGR 4.5%) in emerging markets (generic availability).
- Generic ICS share reached 35% in US (up from 22% in 2020).
User case – National health service (UK, 5 million asthma patients): Formulary preference for generic budesonide DPI over branded fluticasone reduced annual ICS spend by US$ 45M (28% savings). Clinical outcomes (exacerbation rates, hospitalizations) unchanged at 24 months.
Application insights: Asthma (78%) – maintenance therapy across all severities (GINA Steps 2-5). COPD (18%) – ICS indicated for eosinophilic phenotype, frequent exacerbators. Others (4%) – allergic rhinitis (nasal sprays), eosinophilic esophagitis.
Guideline-driven prescribing (GINA 2025):
- Step 1: SABA as needed.
- Step 2: Low-dose ICS (plus SABA).
- Step 3: Low-dose ICS/LABA.
- Step 4: Medium-dose ICS/LABA.
- Step 5: High-dose ICS/LABA + add-on therapy.
Regional snapshot: North America leads with 48% revenue share (higher branded drug prices). Europe holds 28% (strong generic penetration). Asia-Pacific fastest-growing (CAGR 4.8%), driven by asthma diagnosis improvement.
Conclusion
The inhaled corticosteroids market is mature but stable, driven by asthma/COPD prevalence and generic expansion. Success depends on device usability, generic competition management, and combination ICS/LABA products. The projected US$ 4.47 billion market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
